Novo Nordisk's STEP UP trial shows that the higher 7.2 mg dose of Wegovy (semaglutide) enables early responders to lose an average of 27.7% body weight after 72 weeks, significantly more than the 2.4 mg dose or placebo. Most weight loss came from fat reduction (84%), with muscle mass largely preserved and muscle function improved. These findings highlight Wegovy's effectiveness and safety in treating obesity, offering hope for better long-term weight management. Novo Nordisk presented these results at the 2026 European Congress on Obesity and plans further publication.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
